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Abstract
Background: Cancer stem cells (CSCs) play an important role in cancer initiation, relapse and metastasis. To date,
no specific medicine has been found to target CSCs as they are resistant to most conventional therapies and
proliferate indefinitely. Compound Kushen Injection (CKI) has been widely used for cancer patients with remarkable
therapeutic effects in Chinese clinical settings for many years. This study focused on whether CKI could inhibit
MCF-7 SP cells in vitro and in vivo.
Methods: The analysis of CKI on SP population and the main genes of Wnt signaling pathway were studied first.
Then we studied the tumorigenicity of SP cells and the effects of CKI on SP cells in vivo. The mice inoculated with
10,000 SP cells were randomly divided into three groups (6 in each group) and treated with CKI, cisplatin and
saline (as a control) respectively for 7 weeks. The tumor formation rates of each group were compared. The main
genes and proteins of the Wnt signaling pathway were analyzed by RT-PCR and western blot.
Results: CKI suppressed the size of SP population (approximately 90%), and down-regulated the main genes of
Wnt signaling pathway. We also determined that MCF-7 SP cells were more tumorigenic than non-SP and
unsorted cells. The Wnt signaling pathway was up-regulated in tumors derived from SP cells compared with that
in tumors from non-SP cells. The tumor formation rate of the CKI Group was 33% (2/6, P < 0.05), and that of
Cisplatin Group was 50%(3/6, P < 0.05), whereas that of the Control Group was 100% (6/6).The RT-PCR and western
blot results indicated that CKI suppressed tumor growth by down-regulating the Wnt/b-catenin pathway, while
cisplatin activated the Wnt/b-catenin pathway and might spare SP cells.
Conclusions: It suggested that CKI may serve as a novel drug targeting cancer stem-like cells, though further
studies are recommended.
Keywords: cancer stem-like cells, side population, Compound Kushen Injection, MCF-7, Wnt/β-catenin signaling,
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Background
Accumulating evidence has indicted that cancer stem
cells (CSCs) are the roots of oncogenesis, cancer relapse
and metastasis as they are resistant to all conventional
therapies, even the advanced targeted therapy [1-6]. To
date, CSCs have been identified in leukemia [7], breast
cancer [8], brain cancer [9], prostate cancer [10], gastro-
intestinal cancer [11], and other cancers with various
techniques. One of them, the side population cell sorting
analysis, is now capable of isolating cells which contain
CSCs [12-17]. CSCs have the ability to exclude the DNA
binding dye, Hoechst33342 through an adenosine tripho-
sphate-binding cassette (ABC) membrane transporter.
Recently, SP cells have been identified in multiple solid
tumors and cancer cell lines including breast cancer
cell line MCF-7 [12-17]. SP cells exhibit characteristics
similar to CSCs because of their ability to proliferate
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other populations. These rare cells have the potential to
survive conventional therapeutics and regenerate cancer
populations, leading to relapse and metastasis. Hence, SP
cells are known as cancer stem-like cells and are a target
for improved cancer therapy.
Compound Kushen Injection (CKI), commonly known
as the Yanshu Injection, is extracted from two herbs
Kushen (Radix Sophorae Flavescentis) and Baituling (Rhi-
zoma smilacis Glabrae) with the primary components
being oxymatrine and matrine [18]. The fingerprint of CKI
is provided as additional file 1. CKI has been extensively
used alone for cancer patients or in combination with che-
motherapy or radiotherapy in Chinese clinical settings for
many years. Previous clinical studies have shown that CKI
attenuates side effects of chemotherapy and radiotherapy
by improving the quality of life, regulating the immune
function of cancer patients and synergizes the therapeutic
effects of chemotherapy and radiotherapy as well [19,20].
It has been demonstrated that CKI suppresses tumor cell
growth by inducing apoptosis [21] and inhibits the migra-
tion, invasion and adhesion capacity by down-regulating
the expression of CD44v6 protein [22]. However, the
underlying anti-cancer mechanisms are not fully
understood.
The abnormal activation of the Wnt/b-catenin signaling
pathway and subsequent upregulation of b-catenin driven
downstream targets – c-Myc and CyclinD1 is associated
with the development of breast cancer [23]. Recent studies
indicate that the Wnt/b-catenin signaling pathway also
plays an important role in the maintenance of CSCs
[24-27]. In addition, Wnt signaling pathway is also acti-
vated in SP breast cancer cells in vitro [14,27]. Accord-
ingly, in order to know the importance of Wnt signaling
pathway in the tumorigenicity of SP cells, the key regula-
tors of the Wnt signaling pathway from tumors derived
from both SP and non-SP cells were tested.
Our initial study revealed that the main component of
CKI, oxymatrine, can decrease both MCF-7 cell viability
and the size of the SP (by approximately 90%) by inhibit-
ing b-catenin, the main component of the Wnt signaling
pathway, in a dose-dependent manner, while cisplatin
(DDP) only inhibits non-SP cells and spares SP cells in
vitro [28]. However, studies of CKI therapy on the regula-
tion of SP cells have never been evaluated. So we studied
the effects of CKI on the treatment of SP cells and its
mechanism.
Methods
Cell culture
Breast cancer cell line MCF-7 was kindly donated by Prof.
Shuren Zhang (Department of Immunology, Cancer Insti-
tute, Peking Union Medical College and Chinese Academy
of Medical Sciences). MCF-7 cells were maintained in
RPMI1640 culture (Invitrogen) supplemented with 10%
fetal bovine serum (Hyclone), 100 units/ml penicillin G,
and 100 μg/ml streptomycin. All cells were cultured at
37°C in a humidified atmosphere containing 5% CO2.
SP cell isolation
Cells were detached from cell culture flasks with 0.25%
trypsin, and viable cells were counted with trypan blue
and collected for inoculation into NOD/SCID mice. The
remaining cells were stained with the fluorescent dye
Hoechst 33342 (Sigma) at a concentration of 5 μg/mL
(37°C for 90 min) as described by Goodell et al.[29] After
washing with HBSS/2% FBS, the cells were incubated with
1 μg/ml propidium iodide to exclude dead cells, cell analy-
sis and sorting were performed on a FACS Vantage SE
(Becton Dickinson) by using a dual-wavelength analysis
(blue, 420-470 nm; red, 660- 680 nm). We collected both
MCF-7 SP and non-SP cells for the experiment.
Tumor formation in an animal model and drug
intervention
For the tumor formation assay, the NOD/SCID female
mice (5-6 weeks old) were purchased from the Animal
Institute of Peking Union Medical College and maintained
under standard conditions according to the guidelines of
the Institutional Animal Care and Use Committee of
Peking University. The mice were allowed to adapt to the
new environment for one week. We first identified the
tumorigenicity of SP cells. Unsorted, SP and non-SP cells
were collected, and cells were resuspended in PBS/Matrigel
(BD Biosciences) (1:1) ranging from 10
3 to 5 × 10
6 cells per
100 μl. Cells were then injected s.c. into the bilateral mam-
mary pads of the mice. The mice were received an estradiol
supplement (0.4 mg/kg s.c., Sigma) every 10 days until the
end of the experiment after cell injection. The mice with-
out tumors were examined visually everyday. Throughout
the study, mice were weighed and tumors were measured
with a caliper twice a week. Tumor volumes were calcu-
lated using the formula (length×width
2/2). When the xeno-
graft tumors grew to proper size, the mice were euthanized
and a portion of the s.c. tumor tissue was collected, fixed
in 4% formalin, and embedded in paraffin for H&E staining
to assess tumor pathology.
For the drug administration assay, an identical protocol
w a sf o l l o w e d .T h em i c ew e r er a n d o m i z e di n t ot h r e eg r o u p s
(6 in each group). SP cells were resuspended in PBS/Matri-
gel (BD Biosciences) (1:1) with 1 × 10
4 cells per 100 μl. 1 ×
10
4 cells were then injected s.c. into the right mammary fat
pad of each mouse at day 0. The CKI group was injected i.
p. with CKI (courtesy of the Shanxi Zhengdong Pharma-
ceutical Co. LTD., Z14021230, China), (2 ml/kg, diluted
with saline in a final volume of 200 ul) every two days, and
the control group was administered with the same volume
of 200 ul saline every two days beginning from 24 hours
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applied with DDP (courtesy of the Yunnan Supertrack Bio-
pharmaceutical Corporation, H53021740, China), (5 mg/
kg, diluted with saline in a final volume of 200 ul, dose
according to Hardman et al.[30]) for three times at Day1,
Day 8, Day 15 post inoculation.
Quantitative RT-PCR (QRT-PCR) analysis
To assess the expression levels of b-catenin, LEF1, TCF4,
CyclinD1, c-Myc, total RNA from cells/tumors was
extracted by Trizol (Invitrogen) according to the manufac-
turer’s instructions. RNA (2 μg) was quantified by spectro-
photometry (DU640, Backman, USA), and reverse
transcribed into cDNA using a RevertiAid™ First Strand
cDNA Synthesis Kit (Fermentas, CA) according to the
manufacturer’s instructions. Reactions were performed
using SYBR Green I Master Mix(Applied Biosystems, CA)
on a GeneAmp 7500 TaqMAN PCR (Applied Biosystems,
CA). PCR conditions were: initial denaturation at 95°C
for 10 min followed by 40 cycles: 95°C,25 s; 55°C, 25 s and
72°C,50 s with a final extension at 72°C for 5 min. The
sequences of the primers used were as follows: b-actin for-
ward, 5’-GAGACCTTCAACACCCCAGCC-3’ and reverse,
5’-AATGTCACGCACGATTTCCC-3’; b-catenin for-
ward, 5’-AAGGTCTGAGGAGCAGCTTC-3’ and reverse,
5’-TGGACCATAACTGCAGCCTT-3’;L E F 1f o r w a r d ,5 ’-
CTACCACGACAAGGCCAGAG-3’ and reverse, 5’-
CAGTGAGGATGGGTAGGGTTG-3’ and TCF4 forward
5’-TCCCACCACATCATACGCTACAC-3’, and reverse,
5’- TCGCTTGCTCTTCTCTGGACAG-3’. CyclinD1
forward, 5’-CGATGCCAACCTCCTCAACGAC-3’ and
reverse, 5’-CCAGCATCCAGGTGGCGACG-3’ and c-
Myc forward 5’-CAGCAAACCTCCTCAGCC-3’,a n d
reverse, 5’-ATTGTTTTCCAACTCCGGGAT-3’.
The amount of each target gene in a given sample was
normalized to the level of b-actin in that sample. The
2
-ΔΔCT method was applied to analyze the relative changes
in gene expression [31].
Western blot assay
Tumors were ground and lysed with the Keygen Total
Protein Extraction Kit (KGP250, Keygen Serving Science,
China) on ice. Tissue debris was removed by centrifuga-
tion at 4°C for 5 min. Tissue extracts were collected, and
the protein concentration was determined by using the
BCA Protein Assay Kit (KGPBCA, Keygen serving science,
China). 60 μg of protein was run on SDS/PAGE gel and,
after electrophoresis, the proteins were transferred to a
PVDF membrane. Primary antibodies including anti-b-
catenin (BD Bioscience, USA), anti-wnt1 (ab15251,
Abcam, UK), anti-CyclinD1 (ab6125, Abcam, UK), anti-c-
Myc (ab32, Abcam, UK) were applied, followed by incuba-
tion with secondary antibodies (Goat Anti-rabbit IgG,
ZB2301; Goat Anti-mouse IgG, ZB2305, Zhongshan
Golden Bridge Biotechnology CO., LTD., China). Blots
were developed by ChemiDoc XRS System (Bio-Rad,
USA).
Statistical analysis
Student’s independent-samples t-test, one-way ANOVA,
and c
2-test were used for statistical analysis by SPSS
10.0 software (SPSS, China, 657180). P <0 . 0 5w a sc o n -
sidered significant.
Results
The effect of CKI on the number of SP cells in vitro
In Figure 1A, the P3 gate showed the SP cells with
Hoechst 33342 negative/dim. SP cells accounted for
approximately 2.7% of total cells. The percentage of SP
population was decreased markedly by treatment with ver-
apamil, which was consistent with the reports that verapa-
mil could prohibit Hoechst 33342 efflux [12].
To determine whether the SP cell number decreased
with CKI treatment, cells were treated with a range of con-
centrations of CKI (30, 50, 70 μl/ml) for 48 hours and then
the SP cells were analyzed by flow cytometry. The results
showed that the size of the SP population was decreased
by CKI treatment in a dose-dependent manner (Figure
1B). However, our previous study didn’tf i n dt h es a m e
phenomena in the cisplatin-treated cells, which were
broadly used as an anti-breast cancer agent [28].
Canonical Wnt/b-catenin pathway analysis on CKI group
in vitro
RT-PCR analysis was used to investigate whether CKI
could down-regulate the expression of the main genes
of Wnt/b-catenin Pathway. Sorted SP cells were treated
with CKI (70 μl/ml) for 48 h and then analyzed by
Quantitative RT-PCR. The study found a dramatic
decrease of b-catenin, CyclinD1, c-Myc at the mRNA
level with CKI treatment (Figure 2).
SP cells are more tumorigenic in vivo
SP (P3) and non- SP (P4) cells were isolated by flow cyto-
metry and collected for this experiment (Figure 3A, B).
Tumorigenicity assays were performed by injecting MCF-
7 unsorted, SP and non-SP cells into NOD/SCID mice.
The SP cells showed higher tumorigenicity than the
unsorted and non-SP cells (Table 1). Notably, 6 of 6, and 5
of 6 mice inoculated with 10,000, and 1,000 SP cells
respectively gave rise to tumors, whereas only 5 of 6, and
2 of 6 inoculations of the same number of the non-SP
c e l l sg r e wt u m o r s ,a n d5o f6 ,a n d3o f6i n o c u l a t i o n so f
the same number of MCF-7 cells grew tumors. The
tumors derived from non-SP cells were smaller than those
from SP cells (Figure 4A, B).
Nine weeks after injection, the injection sites of 1 ×
10
3 tumorigenic SP cells and 1 × 10
3 nontumorigenic
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contained a tumor about 1 cm in diameter, whereas
non-SP injection site contained no detectable tumor
(Figure 4C). The tumor formed by SP cells showed the
typical pathological features of breast cancer (Figure
4D), whereas only normal mouse mammary tissue was
observed by histology at the site of non-SP injection
(Figure 4E).
Wnt signaling pathway is activated in tumors derived
from SP cells
The key regulator of the Wnt/b-catenin signaling pathway,
b-catenin, was first tested. The results showed that the
expression of b-catenin was significantly higher in tumors
derived from SP cells than that in tumors from non-SP
cells at both mRNA and protein level (Figure 5). Wnt1 as
an activator of canonical Wnt/b-catenin signaling in MCF-
7 cells [32] was tested with other downstream genes and
proteins. Quantitative RT-PCR results showed that the
main genes of Wnt/b-catenin signaling Wnt1, CyclinD1,
c-Myc, TCF4, LEF1 expressed markedly higher in tumors
derived from SP compared with those from non-SP (Figure
5A). Moreover, this was associated with a significant
increase of the expression of upstream Wnt1, consistent
with the up-regulation of lower-stream CyclinD1 and
c-Myc at protein level (Figure 5B).
The effect of CKI on SP cells in vivo
Tumor volumes were measured for up to 7 weeks after
inoculation (Figure 6A). Incised tumors among three
groups were compared (Figure 6B). Both the CKI and
DDP groups showed lower tumor formation rates com-
pared to the control group (P < 0.05) (Figure 6C). A repre-
sentative mouse specimen without a tumor was observed
Figure 1 Analysis of SP cells by CKI treatment. (A) MCF-7 cells were labeled with Hoechst 33342 and analyzed by flow cytometry or with the
addition of Verapamil. The percentage of SP cells appeared as the Hoechst low fraction in the P3 is about 2.7%. (B) MCF-7 cells were treated
with CKI (30 μl/ml, 50 μl/ml, 70 μl/ml) for 48 h, and SP cells were analyzed by flow cytometry. P3 gate is the percentage of SP cells. Data from a
representative experiment (from a total of three) are shown.
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Page 4 of 10in the CKI group (Figure 6D), whereas a representative
specimen with a tumor was observed in the control group
(Figure 6E). No body weight loss was observed in the CKI
group, whereas a slight body weight loss was observed in
the DDP group (Figure 6F).
Canonical Wnt/b-catenin pathway analysis on CKI and
DDP group in vivo
Western blot and RT-PCR analyses were used to investi-
gate whether CKI could down-regulate the expression of
the main components of Wnt/b-catenin Pathway. The
s t u d yf o u n dad r a m a t i cd e c r e a s eo fb-catenin with CKI
treatment, but the same down-regulation was not
observed at the mRNA level. Both the related downstream
genes, including TCF4, LEF1, CyclinD1, and c-Myc
expressed significantly lower in tumors of CKI group than
those of control group as well as the key proteins includ-
ing wnt1, CyclinD1, c-Myc (Figure 7), which indicated
that canonical Wnt/b-catenin signaling pathway was inac-
tive in tumors within the CKI group.
The Wnt/b-catenin Pathway of the DDP group was ana-
lyzed at both the protein and mRNA level. The main
genes and proteins in DDP group were comparable to
those in the control group, suggesting that Wnt/b-catenin
Pathway was still active in the DDP group (Figure 7).
Discussion
How to target CSCs has become a major area of research
in recent years. Thus, establishing an appropriate in vivo
cancer stem cell model is critical for the study of the
treatment of CSCs. Our studies confirmed that SP cells
sorted by flow cytometry from human breast cancer cell
Figure 2 The main genes of Wnt/b-catenin pathway was down-
regulated in the CKI group in vitro. Quantitative RT-PCR analysis
revealed that the expression of b-catenin, CyclinD1 and c-Myc
(mean ± SD) were lower in CKI group than those in the control
group. Most of the differences were statistically significant (** P <
0.01,*** P < 0.001).
Figure 3 Cell sorting results. MCF-7 cells were labeled with Hoechst 33342 and analyzed by flow cytometry (A) or with the addition of
Verapamil (B) SP cells appeared as the Hoechst low fraction in the P3 gate about 2.5%, while non-SP cells retained high levels of Hoechst
staining in the P4 gate. Both SP and non-SP cells were sorted, respectively.
Table 1 Tumorigenicity of SP Cells in NOD/SCID
Xenotransplant Assay
Cells injected/fat pad Tumors/injections
5×1 0
6 1×1 0
5 1×1 0
4 1×1 0
3
Unsorted 6/6 5/6 5/6 3/6
SP ——6/6 5/6
Non-SP ——5/6 2/6
Table showing the number of tumors generated in NOD/SCID mouse fat pads
by SP, non-SP, and unsorted cells. Tumor formation by 1 × 10
4 cells was
observed for 6 weeks after injection, whereas tumor formation by 1 × 10
3
cells was observed for 9 weeks after injection.
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Page 5 of 10Figure 4 SP cells were more tumorigenic. (A) Tumor volumes (mean ± SEM) were plotted for 1 × 10
3 cells of each population (SP, non-SP)
injected (n = 6 per group). Tumors derived from SP were larger than those from non-SP. (B) Representative tumors due to injection of SP cells
(1 × 10
4 cells, 1 × 10
3 cells) compared with non-SP injection (1 × 10
4 cells, 1 × 10
3 cells). (C) A representative tumor in a mouse specimen at the
SP injection (1 × 10
3 cells) site, but not at the non-SP injection (1 × 10
3 cells) site. Histology from the SP injection site ((D), Original
magnification, ×200) contained malignant cells, whereas the non-SP injection site ((E), Original magnification, ×200) revealed only normal
mammary tissue.
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+CD24
- cells
and had greater tumorigenicity than non-SP and
unsorted cells, which indicates SP cells enrich CSCs. The
tumorigenic rate of the mice inoculated with 10,000 SP
cells is 100% (6/6), based on which we created a mouse
model for the drug intervention study of SP cells. CKI
has been widely used in Chinese clinics for many years
with the remarkable effects of controlling tumor size and
improving the quality of life among cancer patients. But
the underlying mechanism has yet to be determined. Our
group was the first to show that CKI suppressed cancer-
stem like cells (SP) in vitro and in vivo in comparison to
the control group.
Wnts are secreted lipid-modified signaling proteins
that initiate the canonical Wnt/b-catenin pathway [33],
resulting in the accumulation of cytoplasmic (signaling)
b-catenin, which are then able to bind the T cell factor/
lymphoid enhancer Factor (TCF/LEF) family of tran-
scription factors and to induce the transcriptional activ-
ities of targeted genes including CyclinD1, c-Myc,
CD44, and matrix metalloproteinase 7 (MMP7), etc
[34,35]. In the absence of Wnt signaling, the level of b-
catenin is kept low through degradation. The Wnt sig-
naling pathway plays a critical role for the maintenance of
CSCs of various cancers [24-26,36-38]. The RT-PCR and
western blot analyses showed that Wnt signaling pathway
was activated in tumors derived from SP cells, but down-
regulated in tumors derived from non-SP cells. It was
reported that the aberrant activation of the canonical
Wnt/b-catenin signaling pathway is associated with tumor
development and progression [23,24,39-41]. Therefore the
up-regulation of Wnt signaling pathway correlates with
the tumor progression, which explains the high tumori-
genicity of SP cells. The results showed that the CKI
down-regulated Wnt/b-catenin signaling pathway in vitro
and in vivo, but the down-regulation of b-catenin was not
observed at the mRNA level in vivo, suggesting that the
underlying mechanism is not transcriptional activation but
the increased degradation of b-catenin via the destruction
complex [42]. Thus, we surmise that the effect of CKI on
SP cells may be related to the down-regulation of the
Wnt/b-catenin signaling pathway.
The asymmetric division of each CSC allows it to gener-
ate one stem cell and another cell that differentiates [43].
So drugs only targeting on differentiated cells will ulti-
mately fail to inhibit tumor growth. Chemotherapeutic
drugs are known to be resistant to CSCs which have the
capacity to efflux drugs by ABC drug pumps [2,3]. In this
study, the DDP suppressed the tumorigenicity of SP cells
but the DDP activated the Wnt/b-catenin signaling path-
way. Our in vitro study demonstrated that the activation
of the Wnt pathway promotes the proliferation and self-
r e n e w a lo fS Pc e l l s ,a n dt h eD D Po n l yi n h i b i t sn o n - S P
cells (differentiated cells) leading to the survival of cancer-
stem like cells (SP cells) [28], which is also consistent with
other studies related to the use of chemotherapeutic drugs
[44-46]. Hence, we postulate that the DDP inhibits the dif-
ferentiated cells derived from SP cells which accounts for
97~98% of MCF-7 cell line leading to a decrease of tumor
size, but spares the SP cells endowed with drug-resistance
properties and activates the Wnt pathway [44], which
requires longer latency period of tumor formation. Further
prolonged study is required to demonstrate this.
We also observed that this study has some limitations
owing to the use of NOD/SCID mice. In clinical settings,
we administered CKI intravenously to cancer patients
daily for 2-3 courses (a course consists of 2-3 weeks).
Based on this, we injected CKI into NOD/SCID mice i.p.
daily. However, the NOD/SCID mice gradually died from
Figure 5 Wnt/b-catenin was up-regulated in tumors derived
from SP cells.(A) Quantitative RT-PCR analysis revealed that the
expression of b-catenin, TCF4, LEF1, CyclinD1 and c-Myc (mean ±
SD) were higher in tumors derived from SP than those in tumors
from non-SP. These differences were all statistically significant (* P <
0.05, ***P < 0.001). (B) Western blotting analysis showed that Wnt1,
b-catenin, CyclinD1 and c-Myc in tumors derived from SP expressed
higher than those in tumors from non-SP cells. The experiment was
run in triplicate.
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Page 7 of 10Figure 6 In vivo efficacy of CKI in the MCF-7 SP xenograft model. (A) Tumor volumes (Mean ± SEM) were plotted for each group (n = 6
per group). Both CKI and DDP suppressed tumor growth. (B) A representative comparison image of the incised tumors from CKI, DDP, and the
control group. (C) The tumor formation rate of the control group was 100% (6/6), while that of CKI group was 33.33% (2/6) and that of the DDP
group was 50% (3/6) (* P < 0.05). (D) A representative mouse specimen without a tumor from the CKI group. (E) A representative specimen with
a tumor from the control group. (F) Schematic outline of mice body weight (mean ± SD). No body weight loss was observed in the CKI group,
but a slight body weight loss was observed in the DDP group compared to the control group.
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Page 8 of 10a dramatic weight loss about one month post-xenotrans-
plantation in both control group and the CKI group,
which didn’to c c u ri nt h eD D Pg r o u pt h a tw a sg i v e na n
injection once a week for three weeks. We attributed this
to the severe immune deficiency of NOD/SCID mice
which couldn’t endure the daily injections of i.p. stimuli.
Subsequently, we changed our drug administration to
every other day and thereafter mice from CKI group dis-
played no abnormal weight loss.
Conclusions
In summary, CKI suppressed MCF-7 SP cells in vitro and
in vivo which may be caused by the down-regulation of the
Wnt/b-catenin signaling pathway. It suggests that CKI may
serve as a novel drug targeting CSCs. In Chinese clinics,
we commonly administer CKI to synergizes the therapeutic
effects of chemotherapy or radiotherapy. Since CKI specifi-
cally suppresses SP cells and cisplatin is known to inhibit
non-SP cells, future studies may combine them together to
determine the effects on suppressing the tumorigenicity of
SP cells. In addition, further studies are warranted to con-
firm the effects of CKI on cancer stem-like cells of other
cancer cell lines and primary carcinomas.
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List of Abbreviations
CSCs: cancer stem cells; SP: side population; CKI: Compound Kushen
Injection; NOD/SCID: non-obese diabetic/severe-combined immunodeficient;
DDP: cisplatin; HBSS: Hank’s balanced salt solution; H&E: hematoxylin and
eosin; LEF: lymphoid enhancer factor; TCF: T-cell factor; MMP:matrix
metalloproteinase; FACS: fluorescence activating cell sorter; ABC: adenosine
triphosphate-binding cassette
Acknowledgements
We thank Dr. Ma Shiliang (Peking University Health Science Center, Beijing,
China) for assisting in cell sorting by FACS. This paper was supported by
Grants No.30772867 from the National Nature Science Foundation of China
and No.2006BAI04A05 from the Eleventh Five-Year Program of the National
Science and Technology Project.
Author details
1Oncology Department, Guang An Men Hospital, China Academy of Chinese
Medical Sciences, No.5 Bei Xian Ge Street, Xicheng District, Beijing 100053,
China.
2Department of Hematology and Oncology, Dong Zhi Men Hospital
Affiliated to Beijing University of Chinese Medicine, No. 5, Haiyuncang,
Dongcheng District, Beijing 100700, China.
3Endocrinology Department,
Guang An Men Hospital, China Academy of Chinese Medical Sciences, No.5
Bei Xian Ge Street, Xicheng District, Beijing 100053, China.
Authors’ contributions
LHS and ZY conceived of the study. XWR did the cell culture, cell isolation,
and wrote this paper. XWR, ZZZ and YLL did in vivo experiments. XWR and
ZXY did RT-PCR and Western Blot. LHS, ZY, CXY, HBJ, HW, QX and PYX
participated in the study design and coordination. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 11 August 2011 Accepted: 28 October 2011
Published: 28 October 2011
References
1. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and
cancer stem cells. Nature 2001, 414:105-111.
2. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med
2002, 53:615-627.
3. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ,
Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP: The ABC
transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells
and is a molecular determinant of the side-population phenotype. Nat
Med 2001, 7:1028-1034.
Figure 7 The Wnt/b-catenin pathway was down-regulated in
the CKI group and up-regulated in the DDP group.a
Quantitative RT-PCR analysis revealed that the expression of b-
catenin, TCF4, LEF1, CyclinD1 and c-Myc (mean ± SD) were lower in
CKI group than those in the control group. Most of the differences
were statistically significant (* P < 0.05). The expression of b-catenin,
TCF4, LEF1, CyclinD1 and c-Myc (mean ± SD) in DDP group were
comparable to those in the control group. b Western blot analysis
showed that Wnt1, b-catenin, CyclinD1 and c-Myc in the CKI group
were significantly lower than those observed in the control group.
The protein level of Wnt1, b-catenin, CyclinD1, and c-Myc in DDP
group were comparable to those in the control group. The
experiment was run in triplicate.
Xu et al. Journal of Experimental & Clinical Cancer Research 2011, 30:103
http://www.jeccr.com/content/30/1/103
Page 9 of 104. Bao S, Wu Q, Mclendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW,
Bigner DD, Rich JN: Glioma stem cells promote radioresistance by
preferential activation of the DNA damage response. Nature 2006,
444:756-760.
5. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L,
Holyoake TL: Primitive, quiescent, Philadelphia-positive stem cells from
patients with chronic myeloid leukemia are insensitive to STI571 in vitro.
Blood 2002, 99:319-325.
6. Reim F, Dombrowski Y, Ritter C, Buttmann M, Hausler S, Ossadnik M,
Krockenberger M, Beier D, Beier CP, Dietl J, Becker JC, Honig A,
Wischhusen J: Immunoselection of breast and ovarian cancer cells with
trastuzumab and natural killer cells: selective escape of CD44high/
CD24low/HER2low breast cancer stem cells. Cancer Res 2009,
69:8058-8066.
7. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a
hierarchy that originates from a primitive hematopoietic cell. Nat Med
1997, 3:730-737.
8. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF:
Prospective identification of tumorigenic breast cancer cells. Proc Natl
Acad Sci USA 2003, 100:3983-3988.
9. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM,
Cusimano MD, Dirks PB: Identification of human brain tumour initiating
cells. Nature 2004, 432:396-401.
10. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT:
CD133, a novel marker for human prostatic epithelial stem cells. J Cell
Sci 2004, 117:3539-3545.
11. Haraguchi N, Inoue H, Tanaka F, Mimori K, Utsunomiya T, Sasaki A, Mori M:
Cancer stem cells in human gastrointestinal cancers. Hum Cell 2006,
19:24-29.
12. Kondo T, Setoguchi T, Taga T: Persistence of a small subpopulation of
cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA
2004, 101:781-786.
13. Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF,
Mori M: Characterization of a side population of cancer cells from
human gastrointestinal system. Stem Cells 2006, 24:506-513.
14. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K,
Tang DG: Side population is enriched in tumorigenic, stem-like cancer
cells, whereas ABCG2+ and ABCG2- cancer cells are similarly
tumorigenic. Cancer Res 2005, 65:6207-6219.
15. Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH: Identification of cancer stem
cell-like side population cells in human nasopharyngeal carcinoma cell
line. Cancer Res 2007, 67:3716-3724.
16. Brown MD, Gilmore PE, Hart CA, Samuel JD, Ramani VA, George NJ,
Clarke NW: Characterization of benign and malignant prostate epithelial
Hoechst 33342 side populations. Prostate 2007, 67:1384-1396.
17. Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F: Cancer stem
cell characteristics in retinoblastoma. Mol Vis 2005, 11:729-737.
18. Tian J, Wang WH, Gao HM, Wang ZM: [Determination of matrine,
sophoridine and oxymatrine in Compound Kushen Injection by HPLC].
Zhongguo Zhong Yao Za Zhi 2007, 32:222-224.
19. Wang ZY, Li GS, Huang HX: [Clinical observation on treatment of 75 mid-
late stage cancer patients with yanshu Injection]. Zhongguo Zhong Xi Yi
Jie He Za Zhi 2006, 26:681-684.
20. Chen J, Mei Q, Xu YC, Du J, Wei Y, Xu ZM: [Effects of Matrine Injection on
T-lymphocyte subsets of patients with malignant tumor after gamma
knife radiosurgery]. Zhong Xi Yi Jie He Xue Bao 2006, 4:78-79.
21. Dai ZJ, Gao J, Wang XJ, Ji ZZ, Wu WY, Liu XX, Kang HF, Guan HT, Ren HT:
[Apoptotic mechanism of gastric carcinoma cells induced by matrine
injection]. Zhonghua Wei Chang Wai Ke Za Zhi 2008, 11:261-265.
22. Dai ZJ, Gao J, Wu WY, Wang XJ, Li ZF, Kang HF, Liu XX, Ma XB: [Effect of
matrine injections on invasion and metastasis of gastric carcinoma SGC-
7901 cells in vitro]. Zhong Yao Cai 2007, 30:815-819.
23. Brown AM: Wnt signaling in breast cancer: have we come full circle?
Breast Cancer Res 2001, 3:351-355.
24. Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, Zhang SH, Huang DD,
Tang L, Kong XN, Chen C, Liu SQ, Wu MC, Wang HY: Wnt/beta-catenin
signaling contributes to activation of normal and tumorigenic liver
progenitor cells. Cancer Res 2008, 68:4287-4295.
25. Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houdellier N,
Ruidavets JB, Mansat-De Mas V, Rigal-Huguet F, Laurent G, Payrastre B,
Manenti S, Racaud-Sultan C: Expression of beta-catenin by acute myeloid
leukemia cells predicts enhanced clonogenic capacities and poor
prognosis. Leukemia 2006, 20:1211-1216.
26. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P,
Huber M, Hohl D, Cano A, Birchmeier W, Huelsken J: Cutaneous cancer
stem cell maintenance is dependent on beta-catenin signalling. Nature
2008, 452:650-653.
27. Li X, Ren J: [Isolation of CD44+/CD24 -/low and side population cells
from MDA-MB-453 cells and the analysis of their activation of Wnt and
Notch pathway]. Beijing Da Xue Xue Bao 2008, 40:471-475.
28. Zhang Y, Piao B, Hua B, Hou W, Xu W, Qi X, Zhu X, Pei Y, Lin H:
Oxymatrine diminishes the side population and inhibits the expression
of beta-catenin in MCF-7 breast cancer cells. Med Oncol 2010.
29. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC: Isolation and
functional properties of murine hematopoietic stem cells that are
replicating in vivo. J Exp Med 1996, 183:1797-1806.
30. Hardman WE, Moyer MP, Cameron IL: Efficacy of treatment of colon, lung
and breast human carcinoma xenografts with: doxorubicin, cisplatin,
irinotecan or topotecan. Anticancer Res 1999, 19:2269-2274.
31. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001, 25:402-408.
32. He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, Mccormick F,
Jablons DM: A monoclonal antibody against Wnt-1 induces apoptosis in
human cancer cells. Neoplasia 2004, 6:7-14.
33. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T,
Yates JR, Nusse R: Wnt proteins are lipid-modified and can act as stem
cell growth factors. Nature 2003, 423:448-452.
34. Behrens J, Von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R,
Birchmeier W: Functional interaction of beta-catenin with the
transcription factor LEF-1. Nature 1996, 382:638-642.
35. Cadigan KM, Nusse R: Wnt signaling: a common theme in animal
development. Genes Dev 1997, 11:3286-3305.
36. Khan NI, Bradstock KF, Bendall LJ: Activation of Wnt/beta-catenin pathway
mediates growth and survival in B-cell progenitor acute lymphoblastic
leukaemia. Br J Haematol 2007, 138:338-348.
37. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM:
WNT/beta-catenin mediates radiation resistance of mouse mammary
progenitor cells. Proc Natl Acad Sci USA 2007, 104:618-623.
38. Schulenburg A, Cech P, Herbacek I, Marian B, Wrba F, Valent P, Ulrich-Pur H:
CD44-positive colorectal adenoma cells express the potential stem cell
markers musashi antigen (msi1) and ephrin B2 receptor (EphB2). J Pathol
2007, 213:152-160.
39. Peifer M, Polakis P: Wnt signaling in oncogenesis and embryogenesis–a
look outside the nucleus. Science 2000, 287:1606-1609.
40. Bienz M, Clevers H: Linking colorectal cancer to Wnt signaling. Cell 2000,
103:311-320.
41. Polakis P: Wnt signaling and cancer. Genes Dev 2000, 14:1837-1851.
42. Nelson WJ, Nusse R: Convergence of Wnt, beta-catenin, and cadherin
pathways. Science 2004, 303:1483-1487.
43. Morrison SJ, Kimble J: Asymmetric and symmetric stem-cell divisions in
development and cancer. Nature 2006, 441:1068-1074.
44. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G,
Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T,
Mariani L, Delia D, Calabro E, Pastorino U, Sozzi G: Highly tumorigenic lung
cancer CD133+ cells display stem-like features and are spared by
cisplatin treatment. Proc Natl Acad Sci USA 2009, 106:16281-16286.
45. Cortes-Dericks L, Carboni GL, Schmid RA, Karoubi G: Putative cancer stem
cells in malignant pleural mesothelioma show resistance to cisplatin and
pemetrexed. Int J Oncol 2010, 37:437-444.
46. Honoki K, Fujii H, Kubo A, Kido A, Mori T, Tanaka Y, Tsujiuchi T: Possible
involvement of stem-like populations with elevated ALDH1 in sarcomas
for chemotherapeutic drug resistance. Oncol Rep 2010, 24:501-505.
doi:10.1186/1756-9966-30-103
Cite this article as: Xu et al.: Compound Kushen Injection suppresses
human breast cancer stem-like cells by down-regulating the canonical
Wnt/b-catenin pathway. Journal of Experimental & Clinical Cancer Research
2011 30:103.
Xu et al. Journal of Experimental & Clinical Cancer Research 2011, 30:103
http://www.jeccr.com/content/30/1/103
Page 10 of 10